The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial.

Journal: American heart journal
PMID: 28267480

Abstract

BACKGROUND: The APEX trial assessed the safety and efficacy of extended-duration thromboprophylaxis using betrixaban versus standard dosing of enoxaparin among hospitalized, acutely ill medical patients. The 80-mg betrixaban dose was halved to 40 mg among subjects with severe renal insufficiency and those receiving a concomitant strong P-glycoprotein inhibitor.

Authors

  • C Michael Gibson
    Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. Electronic address: mgibson@bidmc.harvard.edu.
  • Rim Halaby
    Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
  • Serge Korjian
    Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
  • Yazan Daaboul
    Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
  • Douglas F Arbetter
    Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
  • Megan K Yee
    Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
  • Samuel Z Goldhaber
    Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
  • Russel Hull
    RAH Faculty of Medicine, University of Calgary, Alberta, Canada.
  • Adrian F Hernandez
    Division of Cardiology, Duke University and Duke Clinical Research Institute, Durham, NC.
  • Shiao-Ping Lu
    Portola Pharmaceuticals Inc, South San Francisco, CA.
  • Olga Bandman
    Portola Pharmaceuticals Inc, South San Francisco, CA.
  • Janet M Leeds
    Portola Pharmaceuticals Inc, South San Francisco, CA.
  • Alex Gold
    Portola Pharmaceuticals Inc, South San Francisco, CA.
  • Robert A Harrington
    Department of Medicine, Stanford University, Stanford, CA.
  • Alexander T Cohen
    Guy's and St Thomas' Hospitals, London, UK.

Keywords

External Resources

Popular Topics
Recent Journals